Review Papers Claim by Claim

PUS7 in Cancer — succinct verdict

Pseudouridine synthase 7 (PUS7) is presented as a context dependent epitranscriptomic regulator that modifies tRNA, snRNA, and mRNA to promote proliferation, stress adaptation, invasion, and chemoresistance across multiple cancers; the review synthesizes preclinical in vitro and in vivo data and highlights emerging inhibitors but also emphasizes gaps in clinical validation and mechanistic specificity Cells review on PUS7 (2025)

Detailed, critical review and analysis

What the paper claims (core findings)

• PUS7 modifies tRNAs, snRNAs and mRNAs including stress responsive transcripts (eg ATF4) and thereby enhances translation, stress adaptation, proliferation, invasion and metastasis in multiple cancer models PUS7 substrates and functional consequences
• Preclinical genetic and pharmacologic perturbation of PUS7 reduces tumor growth and metastasis in xenografts and metastasis models; reported inhibitors C4 and C17 show in vitro and in vivo activity (not yet clinically validated) Preclinical efficacy of PUS7 perturbation and inhibitors

Strengths of the review

1. Comprehensive synthesis across cancer types with explicit links to mechanistic studies (MYC/MYCN regulation, ATF4 axis, PI3K/AKT/mTOR, Wnt/β-catenin, TYK2-IFN) using primary literature and multiomic techniques PUS7 and oncogenic signaling links
2. Integration of diverse detection methods (BID-seq, DM-Ψ-seq, Nanopore direct RNA-seq, LC-MS) and datasets (TCGA, GEO, GlioVis, GENT2) to map expression patterns and Ψ signatures across tumors Methods and data resources used

Critical limitations, blindspots and cautions

• Predominantly review of preclinical studies: the article itself contains no new human clinical data and explicitly states no new data were produced; clinical biomarker/therapeutic claims therefore remain provisional No new data and need for clinical validation
• Context dependence and apparent bidirectional roles: some cancers show PUS7 upregulation while others show downregulation (eg gastric cancer, papillary thyroid carcinoma), indicating that blanket targeting could be harmful without tumor-context stratification Context dependent PUS7 expression
• Mechanistic specificity remains incomplete: redundancy among PUS family enzymes and overlapping Ψ sites make assignment of phenotypes to PUS7 alone challenging; functional causal links between specific Ψ events and downstream phenotypes require more rigorous loss/gain experiments at single-site resolution Redundancy among PUS enzymes
• Therapeutic readiness: published inhibitors (C4, C17) have encouraging preclinical activity but lack full pharmacokinetic, selectivity, toxicity profiling, and off-target assessment; systemic inhibition risks interference with normal pseudouridylation in healthy tissues Limitations of current PUS7 inhibitors

Where the evidence is strongest

• Functional dependence of MYC/MYCN-driven cancers on a PUS7-mediated pseudouridylation program (ATF4 axis) has mechanistic depth and independent experimental support, including demonstrations that PUS7 perturbation reduces growth of MYC-driven xenografts and that ATF4 rescues some PUS7 loss phenotypes MYC PUS7 ATF4 axis
• Multiple independent in vivo models show that reducing PUS7 expression lowers tumor growth or metastasis in xenografts and tail-vein metastasis assays across GBM, neuroblastoma, colorectal and pancreatic models In vivo evidence for PUS7 role

Practical recommendations for researchers

1. Use conditional/tissue specific PUS7 knockout mouse models and rescue with catalytically inactive mutants to separate enzymatic from scaffolding functions (authors also recommend this) Need for conditional knockout models
2. Map single-site Ψ changes after PUS7 perturbation using orthogonal methods (BID-seq, Nanopore, mass spec) and pair with ribosome profiling, proteomics, and functional site mutagenesis to ascribe causal links to phenotype Methodological triangulation recommended
3. Assess inhibitor selectivity and safety with comprehensive PK/PD, off-target profiling and testing in normal proliferative tissues (bone marrow, gut, heart, liver) because PUS7 is expressed in several normal tissues and pseudouridylation is essential for physiology Need for inhibitor safety profiling

Figure recreation and quick visualization

Conclusions and confidence

Conclusion: The review convincingly synthesizes growing preclinical evidence that PUS7 can act as an oncogenic facilitator in many contexts by reprogramming translation and stress responses, identifies candidate inhibitors and realistic translational hurdles, and correctly emphasizes the need for mechanistic resolution and clinical validation Paper conclusion on PUS7 role

Confidence in the specific translational claims is moderate because the majority of evidence is preclinical and because of enzyme redundancy, context-dependence, and limited inhibitor characterization.

Useful links and next steps

Author review pages

• Author Q.Y. review
• Author T.G.B. review
• Author A.A.-H. review